Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

2.

Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications.

Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, Liaw YF.

J Biomed Sci. 2003 Jan-Feb;10(1):120-35.

PMID:
12566993
3.

Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis.

Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS, Yeh CT, Chang KS, Huang SN, Kuo GC, Liaw YF.

Hepatology. 2000 Mar;31(3):656-64.

PMID:
10706556
4.

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity.

Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, Huang JH, Kuo GC, Liaw YF.

Gastroenterology. 1998 Oct;115(4):954-65.

PMID:
9753499
5.

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity.

Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC.

Hepatology. 1997 Feb;25(2):449-58.

PMID:
9021963
6.
7.

Nutritional, hepatic, and metabolic effects of cachectin/tumor necrosis factor in rats receiving total parenteral nutrition.

Matsui J, Cameron RG, Kurian R, Kuo GC, Jeejeebhoy KN.

Gastroenterology. 1993 Jan;104(1):235-43.

PMID:
8419247
8.

Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor.

Eichacker PQ, Farese A, Hoffman WD, Banks SM, Mouginis T, Richmond S, Kuo GC, Macvittie TJ, Natanson C.

Am Rev Respir Dis. 1992 May;145(5):1023-9.

PMID:
1586042
9.

TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis.

Eichacker PQ, Hoffman WD, Farese A, Banks SM, Kuo GC, MacVittie TJ, Natanson C.

J Appl Physiol (1985). 1991 Nov;71(5):1979-89.

PMID:
1761500
10.

Body composition and metabolic rate in rat during a continuous infusion of cachectin.

Hoshino E, Pichard C, Greenwood CE, Kuo GC, Cameron RG, Kurian R, Kearns JP, Allard JP, Jeejeebhoy KN.

Am J Physiol. 1991 Jan;260(1 Pt 1):E27-36.

PMID:
1987791
11.

Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience.

Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, et al.

J Infect Dis. 1990 Oct;162(4):817-22.

PMID:
2169497
12.

Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).

Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB Jr, Murray CK, Peer GT, Emerson TE Jr, Passey RB, Kuo GC.

Circ Shock. 1990 Mar;30(3):279-92.

PMID:
2178801
13.

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, et al.

J Exp Med. 1989 Nov 1;170(5):1627-33.

14.

Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE.

J Exp Med. 1989 Mar 1;169(3):823-32.

15.

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A, et al.

J Exp Med. 1988 Mar 1;167(3):1211-27.

16.

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A.

Nature. 1987 Dec 17-23;330(6149):662-4.

PMID:
3317066

Supplemental Content

Support Center